Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Pancreatic Neoplasms 10Ovarian Neoplasms 10Fallopian Tube Neoplasms 10Lung Neoplasms 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 4Esophageal Neoplasms 4Endometrial Neoplasms 4Oropharyngeal Neoplasms 3Mouth Neoplasms 3Melanoma 3Inflammatory Breast Neoplasms 3Hypopharyngeal Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Neoplasms, Squamous Cell 2Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Brenner Tumor 2Adenocarcinoma of Lung 2

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Nivolumab 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Adenocarcinoma × Taxes × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡